ACC 2021: Benefit of Rivaroxaban After Extremity Revascularization Is Greater When Taking Into Account Subsequent Events in VOYAGEUR-PAD
Benefits were driven primarily by reductions in acute limb ischemia and peripheral revascularization events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.